WO2014152600A3 - Measurement of cellular fmrp levels for high throughput drug screening and diagnosis of fragile x syndrome - Google Patents

Measurement of cellular fmrp levels for high throughput drug screening and diagnosis of fragile x syndrome Download PDF

Info

Publication number
WO2014152600A3
WO2014152600A3 PCT/US2014/027517 US2014027517W WO2014152600A3 WO 2014152600 A3 WO2014152600 A3 WO 2014152600A3 US 2014027517 W US2014027517 W US 2014027517W WO 2014152600 A3 WO2014152600 A3 WO 2014152600A3
Authority
WO
WIPO (PCT)
Prior art keywords
measurement
fmrp
fragile
syndrome
diagnosis
Prior art date
Application number
PCT/US2014/027517
Other languages
French (fr)
Other versions
WO2014152600A2 (en
Inventor
Wei Zheng
Daman KUMARI
Karen Pearl USDIN
Manju SWAROOP
Original Assignee
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Of America, As Represented By The Secretary, Department Of Health And Human Services filed Critical The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Publication of WO2014152600A2 publication Critical patent/WO2014152600A2/en
Publication of WO2014152600A3 publication Critical patent/WO2014152600A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G01N2800/385—Congenital anomalies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

Kits and methods for the measurement of the FMR1 gene product, FMRP, are disclosed. The present kits include highly selective fluorophore-labeled antibodies that enable Förster (Fluorescence) resonance energy transfer (FRET) assays for the quantification of FMRP, which can in turn be used in methods for treating patients with underlying CCG-repeat mutations and for screening therapeutic moieties.
PCT/US2014/027517 2013-03-15 2014-03-14 Measurement of cellular fmrp levels for high throughput drug screening and diagnosis of fragile x syndrome WO2014152600A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361793577P 2013-03-15 2013-03-15
US61/793,577 2013-03-15

Publications (2)

Publication Number Publication Date
WO2014152600A2 WO2014152600A2 (en) 2014-09-25
WO2014152600A3 true WO2014152600A3 (en) 2015-01-08

Family

ID=50732279

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/027517 WO2014152600A2 (en) 2013-03-15 2014-03-14 Measurement of cellular fmrp levels for high throughput drug screening and diagnosis of fragile x syndrome

Country Status (1)

Country Link
WO (1) WO2014152600A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105784657A (en) * 2016-03-25 2016-07-20 鲁延军 Method for efficiently screening positive clones of monoclonal antibody by using TR-FRET (Time-Resolved Fluorescence Resonance Energy Transfer)
CN112379106B (en) * 2020-11-10 2023-01-10 四川省人民医院 Application of FMR1 protein in diagnosis of renal insufficiency or renal failure

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011137206A1 (en) * 2010-04-30 2011-11-03 Novartis Ag Predictive markers useful in the treatment of fragile x syndrome (fxs)
US20130149722A1 (en) * 2011-06-10 2013-06-13 Research Foundation For Mental Hygiene, Inc. System and Method for Quantifying Fragile X Mental Retardiation 1 Protein in Tissue and Blood Samples

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7855053B2 (en) 2006-07-19 2010-12-21 The Regents Of The University Of California Methods for detecting the presence of expanded CGG repeats in the FMR1 gene 5′ untranslated region

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011137206A1 (en) * 2010-04-30 2011-11-03 Novartis Ag Predictive markers useful in the treatment of fragile x syndrome (fxs)
US20130149722A1 (en) * 2011-06-10 2013-06-13 Research Foundation For Mental Hygiene, Inc. System and Method for Quantifying Fragile X Mental Retardiation 1 Protein in Tissue and Blood Samples

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Application Note of HTRF (Cisbio) Human Interleukin beta (IL1beta) assay", 6 October 2008 (2008-10-06), pages 1 - 5, XP055138286, Retrieved from the Internet <URL:http://www.tecan.com/platform/content/element/3079/AN_INF500_IL1b_HTRF_394951_V1.0.pdf> [retrieved on 20140904] *
FRANÇOIS DEGORCE ET AL: "HTRF: A Technology Tailored for Drug Discovery -A Review of Theoreti- cal Aspects and Recent Applications", CURRENT CHEMICAL GENOMICS, 1 January 2009 (2009-01-01), pages 22 - 32, XP055129390, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2802762/pdf/TOCHGENJ-3-22.pdf> [retrieved on 20140716] *
GABI SCHUTZIUS ET AL: "A quantitative homogeneous assay for fragile X mental retardation 1 protein", JOURNAL OF NEURODEVELOPMENTAL DISORDERS, BIOMED CENTRAL LTD, LONDON, UK, vol. 5, no. 1, 2 April 2013 (2013-04-02), pages 8, XP021145935, ISSN: 1866-1955, DOI: 10.1186/1866-1955-5-8 *

Also Published As

Publication number Publication date
WO2014152600A2 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
CY1121723T1 (en) COMBINATION OF ANTI-LAG-3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES FOR TUMOR TREATMENT
NZ741324A (en) Anti-cd47 antibodies and methods of use
IL254062B (en) Kits comprising anti-ptk7 antibody and use thereof in treating, detecting, diagnosing, or monitoring cancer
EP3080585A4 (en) Biosensors for biological or chemical analysis and methods of manufacturing the same
NZ799532A (en) Methods and means for the production of ig-like molecules
WO2014172046A3 (en) Gene fusions and gene variants associated with cancer
MY197809A (en) Biomarkers and methods of treating pd-1 and pd-l1 related conditions
BR112014027166A2 (en) antibody, nucleic acid, host cell, method for producing an antibody, immunoconjugate, pharmaceutical formulation, treatment method, proliferation inhibiting method and detection methods.
EP3076949A4 (en) Analysis of genomic dna, rna, and proteins in exosomes for diagnosis and theranosis
BR112012020579A2 (en) process for obtaining controlled size phyllosilicate particles, product and product use.
AR090017A1 (en) FGFR1 AGONISTS AND THEIR METHODS OF USE
BRPI0905362A2 (en) High strength steel plate and its production method.
WO2013066369A3 (en) Methods for detecting graft-versus-host disease
MX356866B (en) P53 biomarkers.
WO2012112315A3 (en) Methods for diagnosis of kawasaki disease
BR112016008477A2 (en) BODIES, NUCLEIC ACID, HOST CELL, METHOD OF PRODUCING AN ANTIBODY, IMMUNOCONJUGATE, PHARMACEUTICAL FORMULATION AND USES OF THE ANTIBODY
BR112015010817A2 (en) anti-hemagglutinin antibodies, method of treating, inhibiting or preventing infections, composition, pharmaceutical composition, nucleic acid, host cell, antibody production method and use of anti-hemagglutinin antibody
WO2012135641A3 (en) Aurora kinase inhibitors and methods of making and using thereof
EP2841599A4 (en) Method for identifying agents capable of inducing respiratory sensitization and array and analytical kits for use in the method.
BR112015003032A8 (en) isolated antibodies, isolated nucleic acids, host cell, method of producing an antibody, immunoconjugate, pharmaceutical formulation, use of the antibody and method of treatment of an individual.
FR2908600B1 (en) CAPSICUM MICROENCAPSULE, PROCESS FOR PREPARING THE SAME, AND USE
BR112014029274A2 (en) isolated antibody, pharmaceutical composition, use of the antibody, method for treating rabies infection, kit for treating rabies infection, kit for detecting rabies virus, isolated nucleic acid, and host cell.
EP2431740A4 (en) Method for measurement of equol in biological sample by immunoassay, kit for the measurement, and method for determination of equol production ability of subject
BR112014026440A2 (en) assays, methods and apparatus for assessing rna disruption
EP2504348A4 (en) Methods, reagents and kits for detection of nucleic acid molecules

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14724562

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14724562

Country of ref document: EP

Kind code of ref document: A2